drugset / Trial / NCT07177469
UBT251 Injection Phase II Study (Overweight or Obesity)
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
Timeline
- Start
- 2025-03-14
- Primary completion
- 2025-10-22
- Completion
- 2025-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UBT251 | Unknown | 2 mg | Subcutaneous |
| Subject | UBT251 | Unknown | 4 mg | Subcutaneous |
| Subject | UBT251 | Unknown | 6 mg | Subcutaneous |